Claims

1. Use of a neuroactive steroid for the manufacture of a medicament for treating a human subject suffering from postpartum depression, wherein the neuroactive steroid is allopregnanolone and the medicament is to be administered via:

a continuous intravenous infusion of allopregnanolone ,

wherein:

allopregnanolone is to be administered as a step-up dose of 15-70 μg/kg/hour via a plurality of step doses;

followed by allopregnanolone to be adminstered at 50-100 μg/kg/hour;

followed by allopregnanolone to be administered as a taper dose of 15-70 μg/kg/hour via a plurality of step doses; and

wherein the duration of said continuous intravenous infusion is 60 hours.

2. The use of claim 1, wherein allopregnanolone is provided in a composition comprising a cyclodextrin.

3. The use of claim 1, wherein allopregnanolone is provided at a concentration of 0.1 to 10 mg/mL.

4. The use of claim 1, wherein allopregnanolone is provided at a concentration of 1 to 5 mg/mL.

5. The use of claim 2, wherein the cyclodextrin is present in the composition at a concentration of 25-100 mg/mL of composition.

6. The use of claim 2, wherein the cyclodextrin is present in the composition at a concentration of 25-100 mg/mL of composition and allopregnanolone is provided at a concentration of 1 to 5 mg/mL allopregnanolone.

7. The use of claim 2, wherein the cyclodextrin is sulfo butyl ether β-cyclodextrin.